SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Cardium Therapeutics,
Inc. (OTC Bulletin Board: CDTP) announced today that Cardium's Chairman and
Chief Executive Officer, Christopher J. Reinhard, will present at the
Merriman Curhan Ford Investor Conference taking place September 18-20, 2006
at the Mark Hopkins InterContinental Hotel, San Francisco. The presentation
will take place on September 20, 2006 at 11:45 a.m. Pacific Time. A live
audio webcast of the presentation will be available at
http://www.wsw.com/webcast/mcm4/cdtp.ob/ and will be archived for 30 days
following the conference.
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO )
About Cardium
Cardium Therapeutics, Inc., founded in 2003 and headquartered in San
Diego, is a medical technology company primarily focused on the
development, manufacture and sale of innovative therapeutic products for
cardiovascular and related indications. In October 2005, Cardium acquired a
portfolio of growth factor therapeutics from the Schering AG Group,
Germany, including the later-stage product candidate, Generx(TM), and
completed a $30 million financing. Generx (alferminogene tadenovec) is a
DNA-based growth factor therapeutic being developed for potential use by
interventional cardiologists as a one-time treatment to promote and
stimulate the growth of collateral circulation in the hearts of patients
with ischemic conditions such as recurrent angina. For more information
about Cardium and its businesses, products and therapeutic candidates,
please visit http://www.cardiumthx.com.
In March 2006, Cardium acquired the technologies and products of
InnerCool Therapies, Inc., a San Diego-based medical technology company in
the emerging field of therapeutic hypothermia, which is designed to rapidly
and controllably cool the body in order to reduce cell death and damage
following acute ischemic events such as cardiac arrest or stroke, and to
potentially lessen or prevent associated injuries such as adverse
neurological outcomes. For more information about Cardium's InnerCool
subsidiary and therapeutic hypothermia, including its Celsius Control
System(TM), which has now received regulatory clearance in the U.S., Europe
and Australia, please visit http://www.innercool.com.
In August 2006, Cardium acquired the technologies and products of the
Tissue Repair Company (TRC), a San Diego-based biopharmaceutical company
focused on the development of growth factor therapeutics for the treatment
of severe chronic diabetic wounds. TRC's lead product candidate,
Excellarate, is a DNA-activated collagen gel for topical treatment
formulated with an adenovector delivery carrier encoding human
platelet-derived growth factor-B (PDGF-B). Excellarate is initially being
developed as a single administration for the treatment of non-healing
diabetic foot ulcers. Other potential applications for TRC's Gene Activated
Matrix (GAM) technology include therapeutic angiogenesis (cardiovascular
ischemia, peripheral arterial disease) and orthopedic products, including
hard tissue (bone), soft tissue (ligament, tendon) and cartilage. For more
information about Cardium's Tissue Repair Company subsidiary, please visit
http://www.t-r-co.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this
press release are forward looking and reflect numerous assumptions and
involve a variety of risks and uncertainties, many of which are beyond our
control and may cause actual results to differ materially from stated
expectations. Actual results may also differ substantially from those
described in or contemplated by this press release due to risks and
uncertainties that exist in our operations and business environment,
including, without limitation, our limited experience in the development of
DNA-based cardiovascular therapeutics and therapeutic hypothermia devices,
our dependence upon proprietary technology, our history of operating losses
and accumulated deficits, our reliance on collaborative relationships and
critical personnel, and current and future competition, as well as other
risks described from time to time in filings we make with the Securities
and Exchange Commission. We undertake no obligation to release publicly the
results of any revisions to these forward- looking statements to reflect
events or circumstances arising after the date hereof.
Copyright 2006 Cardium Therapeutics, Inc. All rights reserved.
For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com.
Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium
Therapeutics, Inc.
Gene Activated Matrix(TM) and GAM(TM) are trademarks of Tissue Repair Company.
InnerCool Therapies(R), InnerCool(R) and Celsius Control System(TM) are
trademarks of InnerCool Therapies, Inc.
SOURCE Cardium Therapeutics, Inc.
 back to top
Related links:
http://www.innercool.com
http://www.t-r-co.com http://www.cardiumthx.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
http://www.prnewswire.com/comp/128401.html /
CONTACT:
Press & Investors, Bonnie Ortega, Director,
Investor & Public Relations, Cardium Therapeutics, Inc.,
+1-858-436-1018, InvestorRelations@cardiumthx.com
|
